Skip to main content

Table 2 Evaluation summary

From: Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

Day

Tests and Procedures

Every 3 months for the first 2 years

Follow-up appointment with study doctor, physical examination by study doctor (or family doctor if appointment is over videolink or phone) and complete questionnaire

Blood tests for certain sites (i.e. liver function tests for patients with liver metastases)

Assessment of any side effects or adverse events

Months 3, 6, 12, 18, and 24

CT scan(s) and/or other imaging (MRI, PET or bone scan)a

Every 6 months for years 2–6

Follow-up appointment with study doctor, physical examination by study doctor (or family doctor if appointment is over videolink or phone) and complete questionnaire. Assessment of any side effects or adverse events

  1. a imaging is optional for prostate cancer patients with PSA < 5